Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment

[1]  Yin Li,et al.  Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study) , 2022, BMC cancer.

[2]  Xiaolong Yan,et al.  Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE). , 2022, International journal of surgery.

[3]  Bentong Yu,et al.  Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma , 2022, Journal for ImmunoTherapy of Cancer.

[4]  Minghui He,et al.  Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma , 2022, Journal for ImmunoTherapy of Cancer.

[5]  Hongwei Lin,et al.  The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer—A Phase II Study , 2021, Frontiers in Immunology.

[6]  Ying Cheng,et al.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. , 2021, JAMA.

[7]  W. Mao,et al.  Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma , 2021, JAMA surgery.

[8]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[9]  Yuyan Zheng,et al.  Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). , 2020, European journal of cancer.

[10]  N. Sun,et al.  175P A study of neoadjuvant sintilimab combined with triplet chemotherapy of lipo-paclitaxel, cisplatin, and S-1 for resectable esophageal squamous cell carcinoma (ESCC) , 2020 .

[11]  H. Daiko,et al.  Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma , 2020, Annals of the New York Academy of Sciences.

[12]  R. Tishler,et al.  Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. , 2020, JAMA oncology.

[13]  H. Baba,et al.  Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma , 2020, Cancer science.

[14]  J. Taube,et al.  Neoadjuvant checkpoint blockade for cancer immunotherapy , 2020, Science.

[15]  V. Patel,et al.  The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors , 2019, Journal of Immunotherapy for Cancer.

[16]  R. Kelly.  Emerging Multimodality Approaches to Treat Localized Esophageal Cancer. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[17]  L. Galluzzi,et al.  Macrophages and Metabolism in the Tumor Microenvironment. , 2019, Cell metabolism.

[18]  J. Schellens,et al.  Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  B. Fox,et al.  Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1 , 2018, Journal of Immunotherapy for Cancer.

[20]  A. Broeks,et al.  Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma , 2018, Nature Medicine.

[21]  F. Su,et al.  Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages , 2018, Cell.

[22]  J. Borst,et al.  CD4+ T cell help in cancer immunology and immunotherapy , 2018, Nature Reviews Immunology.

[23]  P. Philip,et al.  Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. , 2018, The oncologist.

[24]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[25]  H. Zhang,et al.  Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis , 2015, Oncotarget.

[26]  M. Caligiuri,et al.  The Broad Spectrum of Human Natural Killer Cell Diversity. , 2017, Immunity.

[27]  Jianming Xu,et al.  Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma , 2017, Oncotarget.

[28]  Pornpimol Charoentong,et al.  Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.

[29]  T. Anagnostou,et al.  The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation , 2016, Front. Immunol..

[30]  S. Kaech,et al.  The multifaceted role of CD4+ T cells in CD8+ T cell memory , 2016, Nature Reviews Immunology.

[31]  S. Misra,et al.  Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. , 2014, World journal of gastrointestinal oncology.

[32]  H. Höfler,et al.  Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy , 2003, Cancer.

[33]  D. Sugarbaker,et al.  Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. , 2001, The Annals of thoracic surgery.

[34]  J. Petiot,et al.  Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.